BeyondSpring (NASDAQ:BYSI) Releases Quarterly Earnings Results, Beats Expectations By $0.49 EPS

BeyondSpring (NASDAQ:BYSI) announced its quarterly earnings results on Wednesday. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.49, FiscalAI reports.

BeyondSpring Trading Up 3.0%

Shares of NASDAQ BYSI traded up $0.04 during midday trading on Thursday, hitting $1.49. 888 shares of the company’s stock were exchanged, compared to its average volume of 23,302. The business’s fifty day moving average price is $1.62 and its two-hundred day moving average price is $1.70. The company has a market cap of $61.39 million, a price-to-earnings ratio of -9.83 and a beta of 0.41. BeyondSpring has a 12-month low of $1.21 and a 12-month high of $3.44.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (d+)” rating on shares of BeyondSpring in a research note on Friday, March 27th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has an average rating of “Sell”.

Institutional Investors Weigh In On BeyondSpring

An institutional investor recently bought a new position in BeyondSpring stock. State Street Corp bought a new position in BeyondSpring Inc. (NASDAQ:BYSI) during the fourth quarter, according to the company in its most recent filing with the SEC. The firm bought 231,120 shares of the company’s stock, valued at approximately $377,000. State Street Corp owned 0.57% of BeyondSpring as of its most recent SEC filing. 40.29% of the stock is owned by hedge funds and other institutional investors.

About BeyondSpring

BeyondSpring Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapies for oncology. Headquartered in Suzhou, China, with corporate operations in New York, the company leverages a versatile drug discovery platform to advance targeted treatments designed to improve outcomes for patients with cancer. BeyondSpring’s pipeline emphasizes agents that modulate the tumor microenvironment and enhance immune response, with an aim to address key unmet needs in supportive care and tumor control.

The company’s lead candidate, plinabulin, is a small-molecule vascular disrupting agent that also exhibits immunomodulatory activity.